Abstract The Human Epidermal Growth Factor Receptor family is composed of 4 structurally
related receptor tyrosine kinases that are involved in many human cancers. The efficacy and …

Background Adoption of molecular pathology in Brazil is currently very limited. Of note, there
are no programs for training new molecular pathologists in the country; thus, documents …

Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly
binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to …

Squamous cell carcinoma (SCC) of the lung represents around 30% of all non-small-cell
lung cancers. Treatment options for nonsquamous histology have increased in recent years …

Objectives Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer
(NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on …

Aim: This pooled safety analysis was conducted to analyze incidence and management of
key dacomitinib-associated adverse drug reactions (ADRs). Patients & methods: Patients …

Context Dacomitinib and poziotinib, irreversible ErbB family blockers, are often used for
treatment of non-small cell lung cancer (NSCLC) in the clinic. Objective This study …

Background: Recent studies showed that the cooperation between c-SRC and EGFR is
responsible for more aggressive phenotype in diverse tumors, including glioblastomas and …

Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show
promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease …

Several drugs gained market authorization based on the demonstration of improved
progression-free survival (PFS), adopted as a primary endpoint in Phase 3 clinical trials. In …